Abstract: Compounds of formula I: as well as pharmaceutically acceptable salts thereof useful as carbapenem antibacterial agents are disclosed wherein X is CH2 or C═O.

Abstract: A process for preparation of a compound of formula I: wherein: R1 represents CH3 or H; and P represents a protecting group; comprising reacting a compound of formula IV:  wherein R1 and P and are defined above and R4 represents triflate or SO2F; in the presence of a catalyst and (R3)3SnCH2OP″, wherein each R3 represents C1-4 lower alkyl, and P″ represents H or a protecting group, to yield the compound of formula I.

Abstract: The present invention relates to a whole cell assay for cathepsin K. The present invention is useful for determining cathepsin K activity in a mammalian cell systems and for identifying and evaluating inhibitors of cathepsin K.

Abstract: Compounds of formula I: as well as pharmaceutically acceptable salts thereof and compositions useful as carbapenem antibacterial agents are disclosed.

Abstract: Disclosed is a 2-phenyl-benzimidazolesulfonic acid according to the formula 1

Abstract: An ionic liquid of the formula K+A−, wherein K and A are as defined herein, can be used in such things as electrochemical cells, supercapacitors, hydraulic liquids, solvents, organic syntheses.

Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds of negative dielectric anisotropy which comprises at least one compound of the formula I1 1

Abstract: An ionic liquid of the formula K+A− wherein K+ and A− are as defined herein, are suitable for use in electrochemical cells and capacitors. These ionic liquids can also be used in catalysis, as inert solvents, and as hydraulic liquids.

Abstract: A combination of a 5HT1B/1D agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine.

Abstract: The present invention generally relates to compositions for storing heat energy in the form of heat of phase transition, and to their use. The compositions of the invention for storing heat comprise at least one heat storage material and at least one auxiliary and are characterized in that the composition comprises at least one heat storage material which has at least one solid/solid phase transition and is solid throughout the application range.

Abstract: The invention relates to a novel process for the alternative preparation of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide or N-methyl-N-[(1R)-1-phenyl-2-((3R)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide, and the novel compounds N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethane] and N-methyl-N[(1R)-1-phenyl-2-((3R)-3-hydroxypyrrolidin-1-yl) ethane], which are prepared as intermediates.

Abstract: The invention relates to reactive liquid crystal compounds of Formula (I), wherein P=polymerizable group, Sp=spacer, X and Z=linking group, n=1, m=0, or 1, A1 and A2=ring structure and R=unsubstituted or substituted alkyl group with the proviso that m=1 and/or R—P—Sp—X group. The composition comprising reactive liquid crystal compounds of formula (I), to linear or cross-linked (co) polymers obtainable by (co) polymerizing said reactive liquid crystals or compositions and to the use of said reactive liquid crystals or compositions for the preparation of linear or cross-linked polymers or polymer films for decorative pigments, cosmetics or security applications, active and passive optical elements, color filters, scattering displays, adhesives or synthetic resins with anisotropic mechanical properties.

Abstract: The present invention relates to a preparation process for 2-arylbenzimidazolesulfonic acids of the formula I: 1

Abstract: Silane compounds of the formula SiR1R2R3R4 wherein R1 to R4 are as defined herein are useful as additives in electrolytes for improving the properties of electrochemical cells.

Abstract: The invention relates to an electrooptical liquid-crystal display having a realignment layer for realigning the liquid crystals, where the field thereof has a significant component parallel to the liquid-crystal layer, containing a liquid-crystalline medium having positive dielectric anisotropy, where the medium comprises at least one mesogenic compound which contains a group of the formula I and at least one compound of formula II wherein L1 is H or F; R1 R2 are H, an alkyl or alkenyl radical having 1 to 15 carbon atoms which may be substituted; Q is a radical of the formula —(O)q (CH2)r—(CF2)s— in which q is 0 or 1; r is 0 or an integer of 1 to 6, and s is an integer of 0 to 6; X is F or Cl, and in the case where s ≠0, is alternatively H, and A1 and A2 are each, independently of one another, a 1,4-cyclohexenylene or trans-1,4-cyclohexylene which may be substituted; 1,4-phenylene in which may be substituted, 1,4-bicyclo[2.2.

Abstract: An electrode having a positive-electrode material. The positive electrode material is a tin oxide doped with F, Cl, Br, I, S, Se, Te, B, N or P anions.

Abstract: The invention relates to a highly orientated flaky pigment being excellent in plane orientation (leafing effect), wherein a hydrated metal oxide and one or more fluorine-containing phosphates represented by the general formulae (A) and (B) shown in below or salts thereof are covered on the surface of a flaky pigment with a pearl gloss. The general formulae: (A) (RfCnH2nO)mPO(OM)3−m (B) (RfSO2NRCnH2nO)mPO(OM)3−m wherein Rf is the same or different and represents linear or branched C3 to C21 perfluoroalkyl group or perfluoroxyalkyl group, n is 1 to 12, m is 1 to 3, M represents hydrogen, alkali metal, ammonium group or substituted ammonium group, and R represents hydrogen or C1 to C3 alkyl group. A process for producing said pigment in a wet process is also disclosed.

Abstract: The present invention relates to the compounds of formula (I) in which X, R1, R2 and R3 are as defined in claim 1. These compounds are cholesteryl acyl transferase (ACAT) inhibitors.

Abstract: 9a-Azalides, and pharmaceutical compositions containing them, are useful in the treatment and prevention of bacterial respiratory and enteric infections in livestock animals, particularly in cattle and swine.

Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.